Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianxiong Cui

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
International Journal of Clinical and Experimental Medicine|May 2, 2015
MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysisJianxiong Cui
Oncology Letters|September 14, 2019
TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinomaDe Zeng, Haoyu Lin, Jianxiong Cui, et al.
Journal of Thoracic Disease|February 27, 2024
High-resolution transcriptomics analysis of CXCL13<sup>+</sup> EPSTI1<sup>+</sup> CDK1<sup>+</sup> cells with a specific focus on lung adenocarcinomaLongjin Zeng, Xu Chen, Jianxiong Cui, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 10, 2023
Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trialTianxiang Cui, Anmei Zhang, Jianxiong Cui, et al.
Frontiers in Molecular Biosciences|February 10, 2022
Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung CancerXianlan Zhao, Jixi Li, Linpeng Zheng, et al.
Cancer Investigation|February 28, 2022
Rapid Progress in Intelligent Radiotherapy and Future ImplementationGuangpeng Chen, Jianxiong Cui, Jindong Qian, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
International Journal of Clinical and Experimental Medicine|May 2, 2015
MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysisJianxiong Cui
Oncology Letters|September 14, 2019
TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinomaDe Zeng, Haoyu Lin, Jianxiong Cui, et al.
Journal of Thoracic Disease|February 27, 2024
High-resolution transcriptomics analysis of CXCL13<sup>+</sup> EPSTI1<sup>+</sup> CDK1<sup>+</sup> cells with a specific focus on lung adenocarcinomaLongjin Zeng, Xu Chen, Jianxiong Cui, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 10, 2023
Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trialTianxiang Cui, Anmei Zhang, Jianxiong Cui, et al.
Frontiers in Molecular Biosciences|February 10, 2022
Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung CancerXianlan Zhao, Jixi Li, Linpeng Zheng, et al.
Cancer Investigation|February 28, 2022
Rapid Progress in Intelligent Radiotherapy and Future ImplementationGuangpeng Chen, Jianxiong Cui, Jindong Qian, et al.
Pageof 1